Shield Therapeutics plc (LON:STX – Get Free Report) shares dropped 15.1% during trading on Tuesday . The stock traded as low as GBX 4.83 and last traded at GBX 5.16. Approximately 6,491,320 shares were traded during trading, an increase of 171% from the average session volume of 2,396,552 shares. The stock had previously closed at GBX 6.08.
Shield Therapeutics Trading Down 15.1%
The company has a debt-to-equity ratio of -146.28, a current ratio of 0.75 and a quick ratio of 2.16. The business’s 50-day moving average is GBX 5.33 and its two-hundred day moving average is GBX 6.91. The firm has a market cap of £55.21 million, a P/E ratio of -5.16 and a beta of 1.77.
Shield Therapeutics Company Profile
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.
See Also
- Five stocks we like better than Shield Therapeutics
- Q3 Earnings Could Be the Catalyst the Market Has Been Waiting For
- AI Is Making Cybersecurity Harder to Ignore—These 3 ETFs Offer a Broad Bet
- Campbell’s Dividend Cut May Reset the Stock, But the Turnaround Still Has to Deliver
- Copper Is the AI Trade No One Priced In—3 Miners With the Most to Gain
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
